

Resource Summary Report

Generated by ASWG on Aug 9, 2026

Brilliant Violet 421(TM) anti-mouse CD152

RRID:AB_10901170

Type: Antibody

Proper Citation

BioLegend Cat# 106311, RRID:AB_10901170

Antibody Information

URL: http://antibodyregistry.org/AB_10901170

Proper Citation: BioLegend Cat# 106311, RRID:AB_10901170

Target Antigen: CD152

Host Organism: armenian hamster

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 421(TM) anti-mouse CD152

Description: This monoclonal targets CD152

Target Organism: mouse

Clone ID: Clone UC10-4B9

Antibody ID: AB_10901170

Vendor: BioLegend

Catalog Number: 106311

Alternative Catalog Numbers: 106312

Record Creation Time: 20250819T235314+0000

Record Last Update: 20250820T064329+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-mouse CD152.

No alerts have been found for Brilliant Violet 421(TM) anti-mouse CD152.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Anastacio Da Costa Carvalho L, et al. (2026) RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma. Cancer immunology research, 14(1), 90.

Duguid A, et al. (2026) miR-93-mediated PTEN suppression and CNS-specific T cell exhaustion shape the leukemia niche in infant KMT2A::AFF1+ B-ALL. Cell reports, 45(5), 117353.

Izzati FN, et al. (2025) Presentation of immunoregulatory sialoglycans on T cells is divergent between mice and humans. Cell reports, 44(7), 115933.

Leng F, et al. (2025) Ultrastable and versatile multimeric ensembles of FoxP3 on microsatellites. Molecular cell, 85(8), 1509.

Boutet M, et al. (2025) Mutations in MLL3 promote breast cancer progression via HIF1?-dependent intratumoral recruitment and differentiation of regulatory T cells. Immunity, 58(8), 2035.

Blanchard L, et al. (2025) Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade. Cell reports. Medicine, 6(6), 102141.

Peng Y, et al. (2025) Tolerance to non-inherited maternal antigen is sustained by LysM+ CD11c+ maternal microchimeric cells. Immunity, 58(9), 2176.

Knorr DA, et al. (2024) Fc?RIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment. Cancer immunology research, 12(3), 322.

Cortellino S, et al. (2022) Fasting renders immunotherapy effective against low-immunogenic breast cancer while reducing side effects. Cell reports, 40(8), 111256.

Tian M, et al. (2021) ACLY ubiquitination by CUL3-KLHL25 induces the reprogramming of fatty acid metabolism to facilitate iTreg differentiation. eLife, 10.